|
Mar 27
|
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 20
|
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
|
|
Jan 2
|
Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024
|
|
Nov 30
|
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
|
|
Nov 7
|
Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update
|
|
Aug 3
|
Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
|